



ISTITUTO CLINICO  
S. ANNA

Seminari del Venerdì del Gruppo di Ricerca Geriatrica

Brescia, 28 giugno 2019



---

# Il punto sull'OSAS nell'anziano

**Piera Ranieri**

Dr.ssa PIERA RANIERI

Dirigente Medico Dipartimento Medicina-Riabilitazione

Responsabile Ambulatorio di PNEUMOLOGIA

e DISTURBI RESPIRATORI del sonno

Istituto Clinico S. Anna (BRESCIA)

# Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study

R Heinzer, S Vat, P Marques-Vidal, H Marti-Soler, D Andrieu, N Tobback, V Mooser, M Preisig, A Malhotra, G Waeber, P Vollenweider, M Taftli,\*  
J Haba-Rubio\*

Coorte 3043 soggetti  
Polisonnografia in 2121 soggetti

Main risk factors associated with presence of SDB:

- Sex
- **Age**
- BMI
- Neck circumference
- waist-to-hip ratio (in women)
- snoring




Figure 1: Prevalence of sleep-disordered breathing and sleep apnoea syndrome, according to age and sex (A) Mild sleep-disordered breathing was defined as  $\geq 5$  to  $< 15$  events per h, moderate was  $\geq 15$  to  $< 30$  events per h, and severe was  $\geq 30$  events per h. Sleep-disordered breathing categories differed by age;  $p < 0.0001$  in men and  $p < 0.0001$  in women. (B) Mild sleep apnoea syndrome was defined as  $\geq 5$  to  $< 15$  events per h and an Epworth score  $> 10$ , moderate was  $\geq 15$  to  $< 30$  events per h and an Epworth score  $> 10$ , and severe was  $\geq 30$  events per h and an Epworth score  $> 10$ . Categories of sleep apnoea syndrome differed by age;  $p < 0.0001$  in men and  $p < 0.0001$  in women.

**Table 1 A review of the literature describing the prevalence of sleep apnoea in older people**


First author [ref.]	Subjects n	Females %	Age yrs	Population	BMI kg per m <sup>2</sup>	Prevalence of SDB %	
						AHI ≥ 5	AHI ≥ 10/ ≥ 15
CARSKADON [24]	40	55	62–86	Community		36	
COLEMAN [25]	83	28	66 ± 5	Sleep clinic		39	
McGINTY [26]	26	0	64.4 ± 4.4	Community			62
ROEHRS [27]	97		61–81	Sleep clinic		27	
SMALLWOOD [28]	30	20	50–80	Community	± 15%	37	
YESAVAGE [29]	41	0	69.5 ± 6.5	18 community and 23 clinic		73	
HOCH [30]	56	52	69.3 ± 5.4	Community	± 20%	5	4
KNIGHT [31]	27	NG	75.8 ± 5.9	Primary care	25	37	
MOSKO [32]	46	65	68.7 ± 6.7	Community		28	16
ANCOLI-ISRAEL [33]	233	65	65–101	Nursing home	30.6 ± 6.0	70	
HOCH [18]	105	53	60–91	Community	25.4 ± 3.8	26	13
PHILIPS [34]	92	52	64.2 ± 8.6	Community	25.6 ± 4.3	15	
ANCOLI-ISRAEL [19]	346	53	72.8 ± 6.1	Community	24.4 ± 4.2		30
	54	57	70.8 ± 6.2	Community	27.2 ± 5.4		32
BIXLER [20]	75	0	65–100	Community		31	24
YOUNG [21]	3448		60–99	Community		54	20
ENDESHAW [35]	58	76	77.7 ± 6.7	Community		56	19
HAAS [22]	3643	52	70.2 ± 6.9	Community	28.2 ± 5.0	46	20
HADER [23]	80	50	74.1 ± 6.3	General medical clinic	26.8 ± 4.6	43	19

BMI: body mass index; SDB: sleep-disordered breathing; AHI: apnoea-hypopnoea index.



# Il rapporto Età-OSA

(Edwards BA et al. Semin Respir Crit Care Med. 2010; 31: 618)



## Physicians Report Sleep Apnea Infrequently in Older and Older Vulnerable Adults

Andrew M. Namen, MD,\*<sup>1</sup> Daniel J. Forest, MD,<sup>§</sup> Karen E. Huang, MS,<sup>‡</sup> Steven R. Feldman, MD, PhD,<sup>‡</sup> William R. Hazzard, MD,<sup>†</sup> Stephen P. Peters, MD, PhD,\* and Edward F. Haponik, MD\*

**OBJECTIVES:** To determine how often outpatient physician visits detect sleep apnea (SA) in older persons in the United States.

**DESIGN:** Retrospective Analysis.

**SETTING:** US non hospital and hospital based clinics.

**PARTICIPANTS:** US physicians.

**MEASUREMENTS:** National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey data from 1993 to 2011 were used to assess the frequency of physicians' coding diagnoses of SA in persons aged 65 and older. Which specialties are most likely to report SA, the most-common comorbid conditions reported with SA, and the likelihood of reporting SA in patient visits for dementia and preoperative care were assessed.

**RESULTS:** From 1993 to 2011, physicians reported SA in 0.3% of all office visits in persons aged 65 and older. SA reported in visits increased from 130,000 in 1993 to 2,070,000 in 2011, with an annual per capita visit reporting rate of 0.07% to 0.74%. In older populations, the proportion of documented SA visits by specialists rose, and that of primary care providers decreased. Older adults with a diagnosis of SA had higher average number of comorbidities than those without SA (1.8 vs 1.3). Reporting SA was low in visits with a diagnosis of dementia and classified as a preoperative visits.


**CONCLUSION:** In two nationwide surveys, SA reporting by physicians in elderly adults was 16 as greater in 2001 as in 1993, although reporting of SA remains infrequent (<1% of visits) even in vulnerable populations. *J Am Geriatr Soc* 2017.

Sleep apnea (SA) is a common condition with major cardiovascular and cerebrovascular morbidity that contributes to rising healthcare costs.<sup>1,2</sup> Persons with SA are at high risk of motor vehicle crashes, cardiovascular disease, and postoperative complications.<sup>3-7</sup> SA syndromes have an estimated population prevalence of 10%<sup>8-10</sup> and are more common in persons with hypertension (30%), congestive heart failure (~60%), hemispheric stroke (~80%), and diabetes mellitus (~35%).<sup>11-14</sup> Reported prevalence of SA increases with age, with estimates up to 57% in community-dwelling older adults, 45% in those with cognitive disorders, and 60% in those with Parkinson's disease.<sup>15-17</sup> Older adults have more comorbid conditions at the time of their SA diagnosis than younger cohorts.<sup>18,19</sup> Those with clinically relevant SA can develop new-onset cardiovascular conditions, such as hypertension, coronary syndromes, stroke, and white matter changes associated with dementia.<sup>20-23</sup> Moreover, the epidemiology of SA in older adults would be expected to differ according to whether sleep laboratory (incorporating polysomnographic, apnea-hypopnea index-based diagnosis) or general clinical signs, symptoms, and associated conditions are used for diagnosis. Nonetheless, up to 93% of women and 80% of men with obstructive SA have not been diagnosed.<sup>10</sup> Whether SA is not recognized in older persons at physician visits is unclear. Using two nationally representative surveys, trends in SA reporting at physician visits of older persons were assessed.



Incremento del 16% dal 1993 al 2001

Report dei DRS <1% delle visite ultra65enni


**POLISONNOGRAFIE eseguite dall'AMBULATORIO DISTURBI RESPIRATORI del SONNO  
Istituto Clinico S.Anna**




**RICHIESTE POLISONNOGRAFIA nel 2018**  
**(n=453) Istituto Clinico s. Anna**



## ESITO PSG stratificata per RICHIESTA



### PREVALENZA DRS ICOSA stratificata per ETA'



# DRS nell'anziano: difficoltà diagnostiche

- Presentazione atipica della malattia (difficoltosa interpretazione dei sintomi spesso correlata in modo causale alla comorbidità e spesso mascherata dalla comorbidità stessa)

# Le stigmati classiche dell'OSA spesso mancano nell'anziano...

(Endeshaw YW. JAGS 2006; 54:1740)

Table 2. Traditional Risk Factors of Obstructive Sleep Apnea According to Obstructive Sleep Apnea Status

Characteristic	AHI <15 (n = 67)	AHI ≥15 (n = 27)	P-value
Age, mean ± SD	77.3 ± 6.1	76.9 ± 7.4	.74
Snoring, n (%) (N = 89)			
<1 time a week	16 (26)	5 (19)	
≥1 times a week	9 (14)	7 (27)	.25
Don't know, n (%)	38 (60)	14 (54)	
Told to be snoring, %	41	56	.22
Body mass index, kg/m <sup>2</sup> , mean ± SD	25.1 ± 3.6	26.7 ± 4.6	.08
AHI/hour of sleep	7 ± 4	32 ± 16	.001

AHI = apnea-hypopnea index; SD = standard deviation.

## ...e la presentazione dell'OSA può sfuggire

**Table 3. Subjective Sleep Characteristics According to Obstructive Sleep Apnea\* (OSA) Status**

Self-Reported Symptoms	Female (n = 67)		Male (n = 27)		Total (N = 94)	
	OSA –	OSA+	OSA –	OSA+	OSA –	OSA+
Problem falling asleep, %	22	17	17	7	21	11
Time to fall asleep, minutes, mean $\pm$ SD	27.5 $\pm$ 27.1	26.4 $\pm$ 19.9	23.0 $\pm$ 28.8	29.1 $\pm$ 32.4	26.8 $\pm$ 27.2	27.1 $\pm$ 28.0
Number of times you wake up, n, mean $\pm$ SD	2.3 $\pm$ 1.4	2.5 $\pm$ 1.3	2.3 $\pm$ 0.5	2.8 $\pm$ 1.3	2.3 $\pm$ 1.3	2.7 $\pm$ 1.3
Problem getting back to sleep, %	21	21	0	40 <sup>†</sup>	17	31
Do not feel well rested in the morning, %	27	75 <sup>‡</sup>	18	39	25	56 <sup>‡</sup>
Number of naps/day, n, mean $\pm$ SD	0.8 $\pm$ 0.6	1.0 $\pm$ 0.5	1.1 $\pm$ 0.3	1.4 $\pm$ 0.9	0.8 $\pm$ 0.6	1.2 $\pm$ 0.8 <sup>†</sup>
Epworth Sleepiness Scale, mean $\pm$ SD	5.1 $\pm$ 2.6	9.2 $\pm$ 4.8 <sup>‡</sup>	7.7 $\pm$ 2.5	7.3 $\pm$ 3.8	5.6 $\pm$ 2.8	8.3 $\pm$ 4.4 <sup>‡</sup>
Nocturia frequency per night, n, mean $\pm$ SD	1.7 $\pm$ 0.9	2.1 $\pm$ 1.4	1.1 $\pm$ 1.0	2.1 $\pm$ .7 <sup>‡</sup>	1.6 $\pm$ 1.0	2.1 $\pm$ 1.1 <sup>†</sup>

\* Apnea-hypopnea index  $\geq$ 15 per hour of sleep.

P < <sup>†</sup>.05, <sup>‡</sup>.01.

# L'OSA è causa importante di nicturia

(Endeshaw YW et al. JAGS 2004; 52:957)

Table 2. Selected Demographic and Clinical Findings by Sleep-Disordered Breathing Category

Finding	A	B	C	P-value*
	AHI 0-9 (n = 26)	AHI 10-24 (n = 21)	AHI $\geq$ 25 (n = 11)	
	Mean $\pm$ Standard Deviation			
Age	76.9 $\pm$ 6.0	79.7 $\pm$ 6.9	76.5 $\pm$ 7.3	.260
Body mass index, kg/m <sup>2</sup>	24.5 $\pm$ 3.8	23.4 $\pm$ 3.0	28.0 $\pm$ 5.7	.010 <sup>†</sup>
Epworth Sleepiness Scale	5.5 $\pm$ 3.8	6.6 $\pm$ 2.4	8.4 $\pm$ 5.4	.100
Geriatric Depression Scale	1.8 $\pm$ 1.4	1.8 $\pm$ 1.8	2.6 $\pm$ 1.9	.380
Mean arterial blood pressure, mmHg	99.9 $\pm$ 11.5	91.9 $\pm$ 11.3	105.2 $\pm$ 14.7	.015 <sup>‡</sup>
Nocturia episodes	1.7 $\pm$ 1.1	1.6 $\pm$ 0.9	2.6 $\pm$ 1.4	.028 <sup>§</sup>

\* Analysis of variance.

<sup>†</sup> C > A (P = .040); C > B (P = .008); (Tukey honestly significant difference (HSD)).

<sup>‡</sup> C > B (P = .021); (Tukey HSD).

<sup>§</sup> C > A (P = .050); C > B (P = .021); (Tukey HSD).


AHI = Apnea Hypopnea Index.

# DRS nell'anziano: difficoltà diagnostiche

- Presentazione atipica della malattia (difficoltosa interpretazione dei sintomi spesso correlata in modo causale alla comorbidità e spesso mascherata dalla comorbidità stessa)
- Le figure professionali che «curano» i pazienti anziani, spesso non sono «formate» per identificare/trattare i disturbi del sonno dell'anziano (che possono essere complessi/multipli)

Re  
An  
Tiff  
Lyn

The p  
porti  
repre  
chara  
diagn  
  
We h  
estim  
at-ris  
likely



## Recognition and Diagnosis of Obstructive Sleep Apnea in Older Americans

Tiffany J. Braley, MD, MS,<sup>1\*</sup> Galit Levi Dunietz, PhD, MPH,<sup>1\*</sup> Ronald D. Chervin, MD, MS,<sup>\*</sup> Lynda D. Lisabeth, PhD, MPH,<sup>‡</sup> Lesli E. Skolarus, MD, MS,<sup>‡</sup> and James F. Burke, MD, MS<sup>‡</sup>

Although traditional correlates of OSA (snoring, sleepiness, hypertension) are recognized triggers for PSG in the general population, many of these characteristics are also attributed to normal aging.

Consequently, older adults who exhibit these characteristics may be more likely than their middle-aged counterparts to escape sleep evaluations.

Older adults may also be less likely to seek medical attention for symptoms that signal OSA in younger individuals or more likely to experience sequelae not classically associated with OSA in younger individuals

**Table 3. Predictors of *International Classification of Diseases, Ninth Revision*, Obstructive Sleep Apnea (OSA) Diagnosis in All Round 3 National Health and Aging Trends Study Fee-for-Service Participants**

Predictors of OSA	Bivariate Model	Multivariate Model
OR (95% Confidence Interval)		
Age (reference 65–69)		
70–74	0.8 (0.5–1.3)	0.9 (0.5–1.4)
75–79	0.8 (0.5–1.2)	0.9 (0.5–1.5)
80–84	0.6 (0.3–0.9)	0.8 (0.4–1.3)
85–89	0.5 (0.3–0.8)	0.8 (0.4–1.5)
≥90	0.2 (0.1–0.5)	0.4 (0.2–1.0)
Male	1.4 (1.0–1.9)	1.4 (1.1–2.0)
Married or cohabiting	1.5 (1.1–2.1)	1.4 (1.0–2.0)
BMI <sup>a</sup>	1.1 (1.1–1.2)	1.1 (1.0–1.1)
Use mobility device	1.4 (1.1–1.9)	1.3 (0.9–1.8)
Pain in last month	1.8 (1.3–2.4)	1.4 (1.0–2.0)
Cardiovascular disease	1.6 (1.1–2.4)	1.1 (0.7–1.7)
Diabetes mellitus	2.2 (1.5–3.1)	1.3 (1.0–1.9)

<sup>a</sup>The odds ratio (OR) for body mass index (BMI) represents the effects of a 1-unit increase in BMI on the odds of OSA diagnosis. For example, the odds of an individual with a BMI of 30.0 kg/m<sup>2</sup> having an OSA diagnosis is (1.1)<sup>4</sup> = 1.46 times that of an individual with a BMI of 26.0 kg/m<sup>2</sup>.

# DRS nell'anziano: difficoltà diagnostiche

- Presentazione atipica della malattia (difficoltosa interpretazione dei sintomi spesso correlata in modo causale alla comorbidità e spesso mascherata dalla comorbidità stessa)
- Le figure professionali che «curano» i pazienti anziani, spesso non sono «formate» per identificare/trattare i disturbi del sonno dell'anziano (che possono essere complessi/multipli)
- Difficoltà di accesso ai laboratori del sonno (soprattutto per l'anziano affetto da elevata comorbidità/non-autosufficiente) E VICEVERSA
- Difficoltà a stabilire a quale livello di AHI/RDI il paziente anziano vada trattato

# OSAS: Chronicity and Need for Long-Term Management

- OSA is associated with long-term morbidity and mortality. For example, in cardiovascular and cerebrovascular disease
  - Autonomic nervous system activation
  - Myocardial effects
  - Increased platelet aggregability and coagulability
- Decrease cognitive function
- Increased risk of depression
- Societal consequences of OSA and excessive sleepiness
  - Motor vehicle accidents
  - Difficulties with work-place performance
- Decrease quality of life

# **DRS come FATTORE DI RISCHIO di STROKE**

# Obstructive sleep apnea and risk of stroke: A meta-analysis of prospective studies

Min Li, Wen-Shang Hou, Xiao-Wei Zhang, Zhen-Yu Tang\*

Department of Neurology, The Second Affiliated Hospital, School of Medicine, Nanchang University, Nanchang 330006, Jiangxi Province, China





Fig. 2. Association between OSA and risk of stroke. OSA: obstructive sleep apnea.

0167-5273/\$ – see front matter © 2014 Elsevier Ireland Ltd. All rights reserved.  
<http://dx.doi.org/10.1016/j.ijcard.2013.12.230>

Cross-sectional Results of the Sleep Heart Health Study



## SHHS

Sahar E., et al. *Am. J. Respir. Crit. Care Med.* 2001, 163:19.

## Association of Sleep-disordered Breathing and the Occurrence of Stroke

### WISCONSIN

Artz M. et al. *Am J Respir Crit Care Med.* 2005; 172: 1447

**Association between SDB and Stroke**

**Dose-response**

TABLE 2. ADJUSTED ODDS RATIOS FOR THE PREVALENCE OF STROKE FOR SUBJECTS GROUPED BY THE APNEA-HYPOPNEA INDEX

AHI (events/h)	Model 1A		Model 2A		Model 3A	
	OR (95% CI), adjusted for age, sex, BMI, alcohol, and smoking	p Value	OR (95% CI), adjusted for age, sex, BMI, alcohol, smoking, and hypertension	p Value	OR (95% CI), adjusted for age, sex, BMI, alcohol, smoking, diabetes, and hypertension	p Value
< 5*	1.0		1.0		1.0	
≥ 5 to < 20	0.50 (0.11-2.33)	0.38	0.48 (0.10-2.27)	0.36	0.49 (0.10-2.81)	0.36
≥ 20	4.33 (1.32-14.24)	0.02	3.87 (1.19-12.63)	0.02	3.83 (1.17-12.56)	0.03

Definition of abbreviations: AHI = apnea-hypopnea index; BMI = body mass index; CI = confidence interval; OR = odds ratio.


\* This category served as the reference group.

# Apnea and Incident Stroke: The Sleep Heart Health Study

Table 3A: Results of Cox proportional hazard model regression hazard of developing incident ischemic stroke among Men, N = 2,462

Covariate	Unadjusted	Adjusted	
		Age -Adjusted	Fully Adjusted <sup>§</sup>
Hazard Ratio (95% Confidence Interval for Ratio of Hazards)			
OAH I			
IV quartile (19.13 – 164.5)	3.91 (1.55, 9.86)	3.05 (1.21, 7.72)	2.86 (1.10, 7.39)
III quartile (9.50 – <19.13)	2.35 (0.89, 6.20)	1.97 (0.74, 5.21)	1.86 (0.70, 4.95)
II quartile (4.05 - <9.50)	1.96 (0.71, 5.40)	1.86 (0.68, 5.13)	1.86 (0.67, 5.12)
I quartile (0 – <4.05)	1.0	1.0	1.0
P-value for test of linear trend for AHI	0.0004	0.006	0.016

Figure 2A.




**Wider data showed an Increased Risk (HR) for Stroke in patients with an AHI > 20**

**6% increase of Stroke risk for each point of AHI**

# Obstructive Sleep Apnea and Serious Adverse Outcomes in Patients with Cardiovascular or Cerebrovascular Disease

*A PRISMA-Compliant Systematic Review and Meta-Analysis*




Xie et al 2014


**OSA may be a significant predictor of serious adverse outcomes following stroke**

# Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial

O. Parra, Á. Sánchez-Armengol, M. Bonnin, A. Arboix, F. Campos-Rodríguez, J. Pérez-Ronchel, J. Durán-Cantolla, G. de la Torre, J.R. González Marcos, M. de la Peña, M. Carmen Jiménez, F. Masa, I. Casado, M. Luz Alonso and J.L. Macarrón



**FIGURE 1.** Flow chart of the study population. AHI: apnoea–hypopnoea index; nCPAP: nasal continuous positive airway pressure.



**FIGURE 2.** Changes in the mean values of the a) Barthel index, b) Canadian scale and c) Rankin score throughout the study. ----: control group; —: nasal continuous positive airway pressure group.

## When will it be time? Evaluation of OSA in stroke and TIA patients


Johnson KG, Johnson DC,

- OSA also has decremental effects on recovery after stroke and longer time spent in rehabilitation, and small-randomized trials have shown benefit in stroke recovery with continuous positive airway pressure (CPAP)
- Despite these reasons to believe that treating OSA with CPAP is an important part of risk factor reduction and stroke recovery, guidelines still do not strongly recommend evaluation and treatment.
- Standard workup after strokes and TIAs involves testing to determine stroke etiology and determining optimal risk factor management. Many of the modifiable risk factors that are commonly tested for have similar or lower adjusted relative risk of stroke than OSA

Table 1: Modifiable Stroke Risk factors

Risk Factor	Adjusted Relative Risk for stroke
Hypertension	1.4 (age 80) 4.0 (age 50)
Smoking	1.8
Diabetes	1.8-6
Atrial fibrillation	2.6-4.5
High cholesterol	2.0
Lupus anticoagulant	1.8
Carotid stenosis	2.0 for asymptomatic
PFO	0.95-1.83
PFO + Atrial Septal Aneurysm	2.98- 4.96 (yearly stroke risk of 4%)
Obstructive Sleep Apnea (AHI > 5)	2.24 (95% CI 1.57-3.19)

AHI: apnea hypopnea index; Adapted from Goldstein et al., [20,21].



# **Funzioni cognitive e Disturbi Respiratori del Sonno**

# Cognitive complaints in obstructive sleep apnea

Tim J.A. Vaessen<sup>a,b,\*</sup>, Sebastiaan Overeem<sup>c,d</sup>, Margriet M. Sitskoorn<sup>b</sup>

Sleep Medicine Reviews 19 (2015) 51–58

Cognitive complaints in OSA patients compared to healthy controls.

Study	Cognitive complaints	p	Comment
<u>Concentration problems</u>			
Chen et al. [6]	Attention & vigilance	↑ .01	
Ulfberg et al. [50]	Concentrating on new tasks	↑ <.05	Odds ratio 7.5
	Performing monotonous tasks	↑ <.05	Odds ratio 20
<u>Memory complaints</u>			
Chen et al. [6]	Memory & learning	↑ .02	
Daurat et al. [7]	Memory capacity	.10	
Hood & Bruck [45]		ns	
Daurat et al. [7]	Memory stability	↑ .012	Cohen's <i>d</i> = .75
Hood & Bruck [45]		ns	
Daurat et al. [7]	Anxious about memory	↑ .009	Cohen's <i>d</i> = .85
Hood & Bruck [45]		ns	
Ulfberg et al. [50]	Learning new tasks	↑ <.05	Odds ratio 9.1
<u>Executive function complaints</u>			
Chen et al. [6]	Emotional control & motivation	↑ .01	
	Abstract thinking & problem solving	.07	

**Although cognitive complaints are common among OSA patients, not every patient is affected to the same degree and reports the same type of cognitive dysfunction**

↑ = more severe cognitive complaints compared to healthy controls; ns = non-significant with no exact *p*-values provided in the paper.

**Recommendations of the Sleep Study Group of the Italian Dementia Research Association (SINDem) on clinical assessment and management of sleep disorders in individuals with mild cognitive impairment and dementia: a clinical review**

**AIMS contribution**

**Approved by the Italian Association of Neurology on February 2014**




Recommendations for the assessment of sleep disorders	Strength of evidence
Sleep disorders are frequent and tend to occur almost invariably in association in patients with cognitive decline : they have to be always carefully investigated using an in-depth sleep history, a physical examination and questionnaires and scales, whenever possible validated with acceptable and definite values of sensitivity and specificity, directly filled by the patient with the support of the direct caregiver, when possible	A
Recommendations for older adults can be considered a good instrument also for individuals with MCI and dementia of the same age when specific recommendations are unsatisfactory or insufficient	A
Instrumental supports should be considered in selected patients, after a referral to a sleep specialist	A

# Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis

Le Shi <sup>a,b</sup>, Si-Jing Chen <sup>b</sup>, Meng-Ying Ma <sup>c</sup>, Yan-Ping Bao <sup>a</sup>, Ying Han <sup>a</sup>, Yu-Mei Wang <sup>d</sup>,  
Jie Shi <sup>a</sup>, Michael V. Vitiello <sup>e</sup>, Lin Lu <sup>b,a,\*</sup>

## SDB

Elwood et al., 2011 [18] (snoring vascular)  
Elwood et al., 2011 [18] (snoring non-vascular)  
Elwood et al., 2011 [18] (sleep apnea vascular)  
Elwood et al., 2011 [18] (sleep apnea non-vascular)  
Yaffe et al., 2011 [31] (AHI  $\geq 15$  events/h)  
Yaffe et al., 2011 [31] (ODI  $\geq 15$  events/h)  
Yaffe et al., 2011 [31] (oxygen saturation  $< 90\%$ )  
Yaffe et al., 2011 [31] (mid STIAY)  
Yaffe et al., 2011 [31] (high STIAY)  
Chang et al., 2013 [14]  
Virta et al., 2013 [33]  
Tsapanou et al., 2015 [17]  
Yaffe et al., 2015 [15]  
Bokenberger et al., 2017 [37]  
Subtotal (I-squared = 55.8%, p = 0.006)



# Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis

Le Shi <sup>a,b</sup>, Si-Jing Chen <sup>b</sup>, Meng-Ying Ma <sup>c</sup>, Yan-Ping Bao <sup>a</sup>, Ying Han <sup>a</sup>, Yu-Mei Wang <sup>d</sup>,  
Jie Shi <sup>a</sup>, Michael V. Vitiello <sup>e</sup>, Lin Lu <sup>b,a,\*</sup>

*Sleep Medicine Reviews xxx (2017) 1–13*

**Sleep Disturbance Breathing (SDB) WAS ASSOCIATED WITH A HIGHER  
INCIDENCE OF ALL-CAUSE DEMENTIA**

**INSOMNIA INCREASED THE RISK OF AD, BUT NOT VASCULAR OR ALL-CAUSE  
DEMENTIA**


# Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment

## A Systematic Review Meta-analysis

Yue Leng, PhD; Claire T. McEvoy, PhD; Isabel E. Allen, PhD; Kristine Yaffe, MD

JAMA Neurol. doi:10.1001/jamaneurol.2017.2180  
Published online August 28, 2017.

**Figure 1. Forest Plot of Prospective Studies on Association Between Sleep-Disordered Breathing and Risk of Cognitive Impairment**



Pooled analysis of the 6 prospective studies (including 212 943 participants) indicated that those with SDB were 26% (risk ratio, 1.26; 95% CI, 1.05-1.50) more likely to develop cognitive impairment, defined by clinically relevant cognitive Decline or risk of dementia

## Association of Sleep-Disordered Breathing With Cognitive Function and Risk of Cognitive Impairment A Systematic Review Meta-analysis

Yue Leng, PhD; Claire T. McEvoy, PhD; Isabel E. Allen, PhD; Kristine Yaffe, MD

**CONCLUSIONS:** Identification of SDB in elderly persons might help to predict future risk of cognitive impairment. Clinicians should closely follow patients who experience significant levels of SDB for the occurrence of cognitive dysfunction and might consider administering full neuropsychological batteries in some instances.


**This is potentially important for the early detection of dementia.**

**This might open up new opportunities for the prevention of cognitive decline and dementia in elderly persons.**

# Obstructive Sleep Apnea And The Risk Of Cognitive Decline in Older

## Adults

Nadia Gosselin, Ph.D.<sup>1-3</sup>, Andrée-Ann Baril, B.Sc.<sup>1-3</sup>, Ricardo S. Osorio, M.D.,<sup>4</sup> Marta Kaminska,<sup>3,5</sup> M.D., M.Sc., and Julie Carrier, Ph.D.<sup>1-3</sup>



# Correlazione DRS e decadimento cognitivo

Several mechanisms have been proposed for the association between SDB and neurocognitive decline, including **hypoxemia, daytime sleepiness, sleep fragmentation, and oxidative stress**.

To date, it remains controversial which is the most likely mechanism, especially in the absence of well-designed interventional studies to help disentangle the causal pathways. Notably, there has been growing attention on the important role that **hypoxemia** might play in the relationship between SDB and cognition.


Findings from the *HypnoLaus study, the Sleep Heart Health Study, the Apnea Positive Pressure Long-term Efficacy Study, and the Study of Osteoporotic Fractures* all suggest **that degree of hypoxemia or oxygen desaturation rather than sleep fragmentation might affect cognitive performance in middle aged and elderly persons**.

Regular intermittent hypoxia may cause vascular dysfunction, kill neurons, and impair the blood-brain barrier, leading to long-term disruption of the brain's microenvironment and synaptic plasticity.

# Obstructive sleep apnoea and Alzheimer's disease: In search of shared pathomechanisms

D. Polsek<sup>a,b,1</sup>, N. Gildeh<sup>a,c,1</sup>, D. Cash<sup>a,d</sup>, R. Winsky-Sommerer<sup>e</sup>, S.C.R. Williams<sup>d</sup>, F. Turkheimer<sup>d</sup>, G.D. Leschziner<sup>a,c,f</sup>, M.J. Morrell<sup>g</sup>, I. Rosenzweig<sup>a,c,\*</sup>

Neuroscience and Biobehavioral Reviews 86 (2018) 142–149





# Neurocognitive Impairment in Obstructive Sleep Apnea

Chitra Lal, MD, D-ABSM, FCCP; Charlie Strange, MD, FCCP; and David Bachman, MD




FIGURE 1. Proposed model for pathogenesis of neurocognitive impairment in OSAS. ApoE4 = apolipoprotein E  $\epsilon$ 4 allele; CHF = congestive heart failure; EDS = excessive daytime sleepiness; ETOH = ethanol; HTN = hypertension; MCI = mild cognitive impairment; OSAS = obstructive sleep apnea syndrome.

# La sonnolenza, non l'insonnia, è marker di fragilità

(Vaz Fragoso C et al. J Am Geriatr Soc 2009; 57:2094–2100)

Table 3. Slow Gait Speed According to the Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI)

Sleep Questionnaire	n/N (%)	Odds Ratio (95% Confidence Interval)	
		Unadjusted	Adjusted*
ESS score			
< 10 (no drowsiness)	126/284 (44.4)	1.00	
≥ 10 (daytime drowsiness)	61/87 (70.1)	2.94 (1.76–4.92)	3.12 (1.72–5.65) <sup>†</sup>
ISI score			
< 8 (no insomnia)	112/216 (51.9)	1.00	
8–14 (subthreshold insomnia)	57/122 (46.7)	0.81 (0.52–1.27)	0.68 (0.39–1.17) <sup>‡</sup>
> 14 (clinical insomnia)	25/39 (64.1)	1.66 (0.82–3.36)	1.01 (0.42–2.44) <sup>‡</sup>

# Cognitive complaints in obstructive sleep apnea

Tim J.A. Vaessen<sup>a,b,\*</sup>, Sebastiaan Overeem<sup>c,d</sup>, Margriet M. Sitskoorn<sup>b</sup>

*Sleep Medicine Reviews 19 (2015) 51–58*

- 1) OSA patients with higher level of **subjective sleepiness** are more likely to report cognitive complaints.**
- 2) Cognitive complaints are not necessarily a sign of objective cognitive impairment.**
- 3) Current validated objective tests for cognition are designed to detect cognitive impairments in brain injured patients and not to specifically assess cognition in OSA.**

# A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness



Junying Zhou<sup>a,b</sup> Macario Camacho<sup>b,c</sup> Xiangdong Tang<sup>a,\*</sup> Clete A. Kushida<sup>b,\*\*</sup>

<sup>a</sup> Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford Hospital and Clinics, Redwood City, CA, USA  
<sup>b</sup> Department of Psychiatry and Behavioral Sciences, Division of Sleep Medicine, Stanford Hospital and Clinics, Redwood City, CA, USA  
<sup>c</sup> Otolaryngology-Head and Neck Surgery, Division of Sleep Surgery and Medicine, Tripler Army Medical Center, Honolulu, HI, USA



## ARTICLE INFORMATION

Received 18 November 2015  
Received in revised form 7 January 2016  
Accepted 15 February 2016  
Available online 2 March 2016

**Keywords:**  
Cognitive function  
Sleepiness  
Obstructive sleep apnea  
Therapeutics  
Continuous positive airway pressure

## ABSTRACT

Excessive daytime sleepiness (EDS) and neurocognitive dysfunction are commonly observed in patients with obstructive sleep apnea (OSA), and these daytime functional deficits can be reversed partly or completely with treatment such as continuous positive airway pressure (CPAP). Although daytime sleepiness is a possible etiology of neurocognitive dysfunction in OSA patients, CPAP is not necessarily beneficial to all patients with OSA. The objective of this review is to summarize the relationship between neurocognitive function and EDS in OSA, as well as the difference in cognitive domains, improvement, and application of CPAP therapy between patients with and without EDS.

Two authors independently searched PubMed/Medline, The Cochrane Library and Scopus through May 27, 2015. Sixty-five articles were included in this review. The literature demonstrated a wide range of neurocognitive deficits in OSA patients with EDS, but no more extensive and complex cognitive domains (eg, executive function) in patients without EDS. However, the current literature had very few studies with large sample sizes and extended follow-up that evaluated the effect of CPAP for OSA in patients with and without sleepiness. CPAP failed to improve cognitive dysfunction in OSA patients without EDS after short-term therapy.

The evidence suggests that daytime sleepiness possibly relates to the domain and extent of cognitive impairments in OSA, and CPAP therapy has little effect on the improvement of cognitive deficits in OSA patients without EDS. We recommend that additional prospective studies be performed to further quantify the relationship between neurocognitive function in OSA patients with and without EDS.

© 2016 Elsevier B.V. All rights reserved.

The evidence suggests that daytime sleepiness possibly relates to the domain and extent of cognitive impairments in OSA, and CPAP therapy has little effect on the improvement of cognitive deficits in OSA patients without EDS.

Effetto sulle funzioni cognitive

Published Ahead of Print on December 30, 2016 as 10.1212/WNL.0000000000003577  
EDITORIAL

The link between sleep-disordered  
breathing and cognition in the elderly  
New opportunities?

**Il trattamento dei DRS nel paziente  
ANZIANO migliora la prognosi?**

## Obstructive sleep apnoea in the elderly: role of continuous positive airway pressure treatment

Miguel Ángel Martínez-García<sup>1,2</sup>, Eusebi Chiner<sup>3</sup>, Luis Hernández<sup>4</sup>,  
Jose Pascual Cortes<sup>5</sup>, Pablo Catalán<sup>6</sup>, Silvia Ponce<sup>7</sup>, Jose Ramón Díaz<sup>8</sup>,  
Ester Pastor<sup>9</sup>, Laura Vígil<sup>10</sup>, Carmen Carmona<sup>2,11</sup>, Josep Maria Montserrat<sup>12</sup>,  
Felipe Aizpuru<sup>13</sup>, Patricia Lloberes<sup>14</sup>, Mercedes Mayos<sup>15</sup>, Maria José Selma<sup>1</sup>,  
Jose Fernando Cifuentes<sup>1</sup> and Alvaro Muñoz<sup>1</sup> on behalf of the Spanish Sleep  
Network<sup>16</sup>

TABLE 1 Baseline characteristics of randomised patients

	All patients	CPAP treatment	No CPAP treatment
<b>Subjects</b>	224	115	109
<b>Age years</b>	75.5±3.9	75.4±3.8	75.6±4.0
<b>Sex male</b>	153 (68.3)	73 (63.5)	80 (73.4)
<b>BMI kg·m<sup>-2</sup></b>	32.9±6.3	33.0±7.3	32.8±5.1
<b>BMI ≥30 kg·m<sup>-2</sup></b>	144 (64.6)	73 (64.0)	71 (65.1)
<b>Neck circumference cm</b>	42.6±3.6	42.6±3.8	42.7±3.5
<b>ESS</b>	9.5±3.8	9.6±4.0	9.3±3.6
<b>ESS ≥10</b>	84 (37.7)	43 (37.4)	41 (38.0)
<b>Sleep study, respiratory polygraphy</b>	152 (68.5)	76 (66.7)	76 (70.4)
<b>Past cardiovascular events</b>	61 (27.2)	31 (26.9)	30 (27.5)
<b>Systemic hypertension</b>	179 (80.3)	92 (80)	87 (79.8)
<b>Psychotropic drug use</b>	66 (29.5)	33 (28.7)	33 (30.3)
<b>AHI event h<sup>-1</sup></b>	50.4±14.9	53.5±15.6	47.2±13.4
<b>Tsat90%</b>	25.9±27.6	29.8±30.6)	21.6±23.1
<b>ODI3%</b>	45.3±18.7	49.6±20.2	40.3±15.4)
<b>Central AHI</b>	2.2±5.7	2.3±6.5	2.1±4.7
<b>Minimum O<sub>2</sub> saturation</b>	72.2±12.9	70.7±12.5	73.9±13.2

Data are presented as n, mean±SD or n (%). BMI: body mass index; ESS: Epworth Sleepiness Scale; AHI: apnoea-hypopnoea index; ODI: oxygen desaturation index; Tsat90%: nighttime spent with an oxygen saturation below 90%.

## Obstructive sleep apnoea in the elderly: role of continuous positive airway pressure treatment

Miguel Ángel Martínez-García<sup>1,2</sup>, Eusebi Chiner<sup>3</sup>, Luis Hernández<sup>4</sup>,  
Jose Pascual Cortes<sup>5</sup>, Pablo Catalán<sup>6</sup>, Silvia Ponce<sup>7</sup>, Jose Ramón Díaz<sup>8</sup>,  
Ester Pastor<sup>9</sup>, Laura Vigil<sup>10</sup>, Carmen Carmona<sup>2,11</sup>, Josep Maria Montserrat<sup>12</sup>,  
Felipe Aizpuru<sup>13</sup>, Patricia Lloberes<sup>14</sup>, Mercedes Mayos<sup>14</sup>, María José Selma<sup>1</sup>,  
Jose Fernando Cifuentes<sup>1</sup> and Alvaro Muñoz on behalf of the Spanish Sleep  
Network<sup>14</sup>




FIGURE 2 Pearson correlation between hours of continuous positive airway pressure (CPAP) use and changes in Quebec Sleep Questionnaire domains: a) hypersomnolence; b) diurnal symptoms; c) nocturnal symptoms; d) emotional; and e) social interactions.

***CPAP treatment resulted in an improvement in quality of life, sleep-related symptoms, anxiety and depression indexes and some neurocognitive aspects in elderly people with severe OSA***

# CPAP Adherence May Slow 1-Year Cognitive Decline in Older Adults with Mild Cognitive Impairment and Apnea

*Kathy C. Richards, PhD,\* Nalaka Gooneratne, MD,<sup>†</sup> Barry Dickey, MD,<sup>‡</sup>  
Alexandra Hanlon, PhD,<sup>§</sup> Stephen Moelter, PhD,<sup>¶</sup> Fannie Onen, MD,<sup>†||\*\*</sup> Yanyan Wang, PhD,<sup>\*††</sup>  
Amy Sawyer, PhD,<sup>§‡‡</sup> Terri Weaver, PhD,<sup>§§¶¶</sup> Alicia Lozano, MS,<sup>§</sup> Patricia Carter, PhD,\* and  
Jerry Johnson, MD<sup>||||</sup>*

54 elderly patients with MCI


MCI +CPAP=29 pts (mean age 67.4±7.2 years)

MCI –CPAP=25 pts (mean age 73.2±8.6 years)

Controlling for baseline differences, 1 year of CPAP adherence in MCI +OSA significantly improved cognition, compared with a nonadherent control group, and may slow the trajectory of cognitive decline.

# Continuous positive airway pressure and survival of very elderly persons with moderate to severe obstructive sleep apnea


Daniel López-Padilla <sup>a,\*</sup>, Rodrigo Alonso-Moralejo <sup>a,b</sup>, Miguel Ángel Martínez-García <sup>cd</sup>, Salvador De la Torre Carazo <sup>a</sup>, María Josefa Díaz de Atauri <sup>a,b,d</sup>



Studio osservazionale, retrospettico  
Soggetti over 80  
oAHI>20 (valori medi 49,2)  
79 # CPAP (>4 ore/notte)  
76# no CPAP (< 4 ore /notte o mancata prescrizione)  
53 mesi di follow up (41-77 mesi)

**Table 2**  
Causes of death according to CPAP treatment.

	Entire population (n = 155)	Treated (n = 79)	Untreated (n = 76)	p
Total	83 (54)	35 (44)	48 (63)	<b>0.02</b>
Cardiovascular	23 (15)	11 (14)	12 (16)	NS
Infections	23 (15)	9 (11)	14 (18)	NS
Malignancy	16 (10)	6 (8)	10 (13)	NS
Other	9 (6)	4 (5)	5 (6)	NS
Unknown	5 (3)	1 (1)	4 (5)	NS



OSA AHI > 30 non trattato

OSA 15 < AHI < 30 non trattato

OSA trattato con CPAP

Gruppo controllo AHI < 15

155 # controls (AHI<15)  
 108# oAHI 15-29 senza CPAP  
 173# oAHI>30 senza CPAP  
 503# oAHI>30 con CPAP  
 69 mesi di follow up medio  
 BMI medio 32.4-35.1  
 Età > 65 anni

## Cardiovascular Mortality in Obstructive Sleep Apnea in the Elderly: Role of Long-Term Continuous Positive Airway Pressure Treatment

A Prospective Observational Study


Miguel-Angel Martínez-García<sup>1,2</sup>, Francisco Campos-Rodríguez<sup>1</sup>, Pablo Catalán-Serra<sup>4</sup>,  
 Juan-José Soler-Cataluña<sup>4</sup>, Carmen Almeida-Gonzalez<sup>1</sup>, Ines De la Cruz Morón<sup>1,5</sup>, Joaquín Durán-Cantolla<sup>2,6</sup>,  
 and Josep-Maria Montserrat<sup>2,7</sup>

# Increased Incidence of Stroke, but Not Coronary Heart Disease, in Elderly Patients With Sleep Apnea Role of Continuous Positive Airway Pressure Treatment

*Stroke.* 2019;50:491-494.

Pablo Catalan-Serra, MD; Francisco Campos-Rodriguez, MD; Nuria Reyes-Nuñez, MD;  
Maria Jose Selma-Ferrer, MD; Cristina Navarro-Soriano, MD; Marta Ballester-Canelles, MD;  
Juan-José Soler-Cataluña, MD; Pilar Roman-Sanchez, MD;  
Carmen V. Almeida-Gonzalez, BSc(Stat); Miguel A. Martinez-Garcia, MD

1005 pts >65 anni



# Increased Incidence of Stroke, but Not Coronary Heart Disease, in Elderly Patients With Sleep Apnea

## Role of Continuous Positive Airway Pressure Treatment

*Stroke.* 2019;50:491-494.

Pablo Catalan-Serra, MD; Francisco Campos-Rodriguez, MD; Nuria Reyes-Nuñez, MD;  
Maria Jose Selma-Ferrer, MD; Cristina Navarro-Soriano, MD; Marta Ballester-Canelles, MD;  
Juan-José Soler-Cataluña, MD; Pilar Roman-Sanchez, MD;  
Carmen V. Almeida-Gonzalez, BSc(Stat); Miguel A. Martinez-Garcia, MD


**In this large, observational study, untreated severe OSA was an independent risk factor for incident stroke, but not for CHD in a clinical population of elderly individuals with suspected OSA.**

**Adequate CPAP therapy may reduce this cerebrovascular risk.**

## The hypoxic burden of sleep apnoea predicts cardiovascular disease-related mortality: the Osteoporotic Fractures in Men Study and the Sleep Heart Health Study

Ali Azarbarzin<sup>1\*</sup>, Scott A. Sands<sup>1</sup>, Katie L. Stone<sup>2,3</sup>, Luigi Taranto-Montemurro<sup>1</sup>, Ludovico Messineo<sup>1</sup>, Philip I. Terrill<sup>4</sup>, Sonia Ancoli-Israel<sup>5,6</sup>, Kristine Ensrud<sup>7</sup>, Shaun Purcell<sup>1,8</sup>, David P. White<sup>1</sup>, Susan Redline<sup>1</sup>, and Andrew Wellman<sup>1</sup>

Outcomes of Sleep Disorders in Older Men (MrOS): 2743 M, Mean age: 76.3 ± 5.5 years  
Sleep Heart Health Study (SHHS): 5111 F, Mean age: 63.7 ± 10.9 years



## Personalized Management Approach for OSA

Jayne C. Carberry, PhD; Jason Amatoury, PhD; and Danny J. Eckert, PhD




Figure 2 – Example of current diagnosis and treatment flow diagram for someone with suspected OSA. As shown by the large number of potential steps, particularly for those who fail CPAP therapy, this schematic highlights the potentially cumbersome, time-consuming, and often frustrating process that many patients with OSA face in their diagnosis and treatment journey. (Note: several therapies and treatment pathways have been omitted for simplicity.) Not surprisingly, many patients are lost to follow-up at various stages throughout the process depending on their experiences and responses to prescribed therapy. Advances in technology (eg, autotitrating CPAP and home sleep testing) have emerged to streamline some of the steps. Similarly, simplified models of care that do not require a sleep specialist have been trialed<sup>2</sup> and have been shown to yield comparable outcomes for certain patient groups (eg, those with severe OSA and minimal comorbidities). However, rather than trial and error, the ultimate goal remains to personalize the management process to deliver one or more targeted therapies according to phenotypic characterization as first-line therapy with high predictive success rates. The text and Figures 1, 3, and 4 provide further details.

# ADERENZA AL TRATTAMENTO

Patients generally make the decision to adhere to CPAP therapy early during the first week of therapy, usually by the second to fourth day. Those who adhere generally increase their duration of nightly use gradually.

As an example, one study demonstrated that patients who used CPAP for more than two years increased their duration of use approximately eight minutes per night during each year of therapy



When you got sleep  
apnea but still  
trying be sexy AF



# **PERCORSO per TITOLAZIONE/ADDESTRAMENTO alla ventilazione notturna a pressione positiva in regime di MAC 06**

(almeno 3 figure professionali, per almeno 120 minuti di attività)

**Pazienti presi in carico:** soggetti con diagnosi di Disturbi Respiratori del Sonno (prevalentemente OSAS) reclutati in fase diagnostica nell'ambulatorio dei disturbi respiratori del Sonno.

L'indicazione al percorso MAC riguarda i pazienti con diagnosi di OSAS moderata/severa con indicazione all'avvio di trattamento con ventilazione a pressione positiva (CPAP/APAP/auto-BiPAP) domiciliare ed è finalizzato alla titolazione/adattamento della ventilazione notturna ed alla formazione/addestramento del paziente alla sua gestione domiciliare.

**Numero di accessi:** in media 5 in un periodo di tre settimane (gruppi di 2 pazienti)

# Figure professionali coinvolte

- ✓ Medico specialista pneumologo
- ✓ Tecnico di fisiopatologia respiratoria
- ✓ Infermiere professionale
- ✓ Tecnico di neurofisiopatologia
- ✓ Psicologo



**REQUISITO fondamentale è che tutte le figure professionali coinvolte abbiano comprovata esperienza nella gestione dei disturbi respiratori del sonno**





## **OBBIETTIVI DEL PERCORSO DI TITOLAZIONE/ADDESTRAMENTO alla ventilazione a pressione positiva:**

- Identificare il livello di CPAP ottimale
- Normalizzare il quadro polisonnografico
- Migliorare i sintomi/qualità del sonno/qualità della vita
- Addestrare il paziente/caregiver all'utilizzo ed alla gestione/igiene domiciliare del ventilatore
- EDUCARE il paziente
- **RIUSCIRE AD OTTENERE LA MASSIMA COMPLIANCE/ADERENZA POSSIBILE**

## EDUCAZIONE DEL PAZIENTE

- Risultati della polisonnografia
- Decorso dell'OSA e patologie correlate
- Conseguenze del mancato trattamento della patologia
- Identificazione e trattamento dei fattori di rischio
- Opzioni di trattamento
- Aspettative dal trattamento
- Il ruolo del paziente nel trattamento
- Preoccupazioni ed obiettivi del paziente



SCIENTIFIC INVESTIGATIONS

**Patient-Reported Outcomes in Older Adults With Obstructive Sleep Apnea Treated With Continuous Positive Airway Pressure Therapy**


Jennifer Pallansch, BS<sup>1</sup>; Yiping Li, MD<sup>2</sup>; James Bena, MS<sup>3</sup>; Lu Wang, MS<sup>3</sup>; Nancy Foldvary-Schaefer, DO, MS<sup>4</sup>

<sup>1</sup>Case Western Reserve University School of Medicine; <sup>2</sup>Kaiser Permanente Los Angeles Medical Center (LAMC); <sup>3</sup>Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; <sup>4</sup>Sleep Disorders Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio

532 pazienti con OSA (26% >60 anni)


COMPLIANCE alla CPAP nei primi 3 mesi:  
70% dei <60 anni vs 79.9% >60 anni

Figure 1—Changes from baseline in PROs between age groups.




Sample sizes of younger and older group are: baseline 393, 139; 3-month 332, 121; 6-month 71, 48; and 12-month 75, 32, respectively.

# COMPLIANCE alla terapia ventilatoria valutata al 1° controllo (40-60 giorni dopo la prescrizione)



# ADERENZA TERAPEUTICA valutata al 1° controllo (40-60 giorni dopo la prescrizione)



**Utilizzo medio: 6,7 ore/die**

# Figure professionali coinvolte nel trattamento di un paziente anziano affetto da DRS

- ✓ Medico specialista pneumologo
- ✓ Tecnico di fisiopatologia respiratoria
- ✓ Infermiere professionale
- ✓ Tecnico di neurofisiopatologia
- ✓ Psicologo



**REQUISITO fondamentale è che tutte le figure professionali coinvolte abbiano comprovata esperienza nella gestione dei disturbi respiratori del sonno**

# Ruolo dello Psicologo



All'inizio del percorso:

- intervista semi-strutturata al fine di indagare il grado di conoscenza sulla patologia presentata e di consapevolezza degli effetti di quest'ultima sulla vita quotidiana
- somministrazione di scale valutative relative alla qualità del sonno percepita dal paziente (**Pittsburg Sleep Quality Index**) ed ai comportamenti di igiene del sonno (**Sleep Hygiene Index**)
- breve valutazione neuropsicologica condotta, utilizzando test di screening cognitivo (dapprima MMSE, attualmente MoCA)

Durante il percorso, in base al livello informativo e motivazionale del paziente nei confronti della patologia OSAS si effettua supporto educativo e supporto motivazionale al fine di implementarne la consapevolezza.

Al termine del percorso (prima della prescrizione):

- si rivalutano i livelli d'informazione riguardo la Sindrome delle Apnee Ostruttive del Sonno e si indagano i livelli di autoregolazione ed autoefficacia relativi al trattamento.
- si somministra **CPAP Questionnaire**, volto a rilevare le impressioni soggettive che il paziente ha rispetto all'utilizzo della CPAP, (valore <20/60 è indice di un'adeguata predittiva aderenza al trattamento).



## Precision medicine in obstructive sleep apnoea

Miguel Angel Martinez-Garcia, Francisco Campos-Rodriguez, Ferrán Barbé, David Gozal, Alvar Agustí

Lancet Respir Med 2019; 7: 456-64

Published Online April 12, 2019

[http://dx.doi.org/10.1016/S2213-2600\(19\)30044-X](http://dx.doi.org/10.1016/S2213-2600(19)30044-X)

Respiratory Department, Polytechnic and University Hospital la Fe, Valencia, Spain (M A Martinez-Garcia MD); Centro de Investigación

Obstructive sleep apnoea (OSA) is a heterogeneous and complex disease; however, diagnosis and management still rely on a simple set of tools and few therapeutic options. Precision medicine has emerged as the next goal for clinical practice, with the objective being to offer individually tailored treatments. Ways of implementing precision medicine in clinical practice have emerged for various respiratory disorders, and such an approach could also be readily exported to OSA. Here, we propose a control panel tool that describes OSA in four domains: disease severity, biological activity, impact on the patient, and pathophysiological traits. We also propose a graphical instrument, the clinical fingerprint tool, to enable the tracking of patients over time. These tools can address the complexity of OSA and guide a physician's course of action on the basis of the treatable traits of an individual patient, thereby facilitating the clinical implementation of precision medicine in the disorder.

Martinez-Garcia MA et al. Lancet Respir Med, April 12, 2019





Figure 2: Obstructive sleep apnoea control panel

## CENTRAL ILLUSTRATION: Domain Management Approach to HF in the Geriatric Patient




Gorodeski, E.Z. et al. J Am Coll Cardiol. 2018;71(17):1921-36.

# TAKE HOME MESSAGES

- Valutare i sintomi (soprattutto SONNOLENZA)
- Valutare la situazione sociale/medica/funzionale/farmacologica (COMPLESSITA' CLINICA)
- Valutare comorbidità neurologica/respiratoria/cardiologica (aritmica)
- Valutare Rapporto costo-beneficio e le aspettative

• AHIa/RDI>30/h



TRATTARE

• AHIa<15



SCARSI DATI

• AHI tra 15 e 30



IN BASE AI SINTOMI

- Valutare TERAPIE ALTERNATIVE...anche se la PRIMA SCELTA nell'anziano rimane SEMPRE la ventilazione

**The good physician treats the disease;  
the great physician treats the patient who has the disease.**

***William Osler***

**Vi ringrazio per l'attenzione**

